| Literature DB >> 30699138 |
María Auxiliadora Sotomayor1, Jessica Karina Reyes1,2, Leda Restrepo1, Cristóbal Domínguez-Borbor1, Martha Maldonado1, Bonny Bayot1,3.
Abstract
Bacterial diseases cause high mortality in Penaeus (Litopenaeus) vannamei postlarvae. Therefore, appropriate application of efficient therapeutic products is of vital importance for disease control. This study evaluated through in vitro analyses the antimicrobial effectiveness of commercial therapeutic products used for P. vannamei bacterial diseases and antibiotics against pathogenic Vibrio strains circulating in Ecuadorian hatcheries. Twenty strains were isolated from 31 larvae samples with high bacterial counts from 10 hatcheries collected during mortality events. The strains virulence was verified through challenge tests with Artemia franciscana nauplii and P. vannamei postlarvae. Through 16S rRNA sequence analysis, strains showed a great similarity to the Vibrio sequences reported as pathogens, with 95% belonging to the Harveyi clade. Through antibiograms and minimal inhibitory concentration (MIC) in vitro tests we found that furazolidone, ciprofloxacin, chloramphenicol, norfloxacin, nalidixic acid, florfenicol, fosfomycin and enrofloxacin inhibited the growth of all or most of the strains. Less efficient antibiotics were penicillin, oxytetracycline and tetracycline. A multiple antibiotic resistance (MAR) index of 0.23 showed some level of resistance to antibiotics, with two MAR prevalent patterns (Penicillin-Oxytetracycline and Penicillin-Oxytetracycline-Tetracycline). From a total of 16 natural products (five probiotics, nine organic acids and two essential oils), only three (one probiotic, one organic acid and one essential oil) were effective to control most of the strains. Shrimp producers can apply relatively simple in vitro analyses, such as those employed in this study, to help take adequate management decisions to reduce the impact of bacterial diseases and increase profit.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30699138 PMCID: PMC6353134 DOI: 10.1371/journal.pone.0210478
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Description of the products marketed in Ecuador as therapeutic agents against shrimp bacterial disease.
| Product code | Declared composition | Declared dosage / dosage used by producers | Presentation | Country manufacturer |
|---|---|---|---|---|
| Probiotic microorganisms: total aerobes | 2–10 μg mL-1 | Powder | USA | |
| Probiotic microorganisms: total aerobes | 5 μg mL-1 | Powder | USA | |
| Strains of | 1 to 5 g kg-1 | Powder | USA | |
| Mixture of strains of | 100–200 g ha-1 | Powder | USA | |
| 10 mL t-1 | Liquid | Ecuador | ||
| Calcium formate, calcium propionate, premix carvacrol and thymol, premix allicin, yeast cell wall, calcium lactate, nucleotide, vitamin C 35%, fumaric acid, calcium citrate, organic zinc, organic manganese, inositol, vitamin E, sodium acetate, benzoic acid, BHT, betaglucans, organic iron, citric acid, niacin, vitamin A, zinc, calcium pantothenate, vitamin B6, potassium sorbate, magnesium chloride, copper sulfate, organic copper, monosodium phosphate, vitamin D3, organic selenium and sodium selenium | 1–7 kg t-1 of feed | Powder | Ecuador | |
| Formic acid, propionic acid, ammonium formate, acetic acid, silic acid and vermiculite | 0.6 kg t-1 of feed | Powder | Austria | |
| Calcium propionate 16%, calcium formate 18% and calcium carbonate 66% | 1–2 kg t-1 | Powder | Ecuador | |
| Propionic acid 25%, formic acid 25% and formaldehyde 15% | 1–3 kg ha-1 | Powder | Ecuador | |
| Formic acid, and its salts, mixture of flavors (essences and plant extracts: | 2–3 kg t -1 of feed | Powder | Spain | |
| Lactic acid 23%, fumaric acid 20%, citric acid 20%, malic acid 25% and succinic acid 10% | 2–4 μg mL-1 | Powder | Ecuador | |
| Acid formic 35.4%, formate 34.6% and potassium 30.0% | 2–5 kg t -1 of feed | Powder | Germany | |
| Formaldehyde 35%: 28.6%, propionic acid 10%, bentonite 39% and silicic acid 22.4% | 1 kg t -1 of feed | Powder | Spain | |
| Mixture of short chain organic acids, acetic acid, propionic acid, formic acid and formaldehyde | 0.5–2 kg t-1 of feed | Powder | Spain | |
| Oregano oil extract | 1–5 mL t-1 | Liquid | USA | |
| Highly concentrated mix of essential oils | 1–10 mL t-1 | Liquid | Spain |
Probiotics: P1, P2, P3, P4 and P5; Organic acids: OA1, OA2, OA3, OA4, OA5, OA6, OA7, OA8 and OA9; Essential oils: EO1 and EO2.
a Specific bacterial strain are not declared in the product
Mortality (average ± standard deviation) of Artemia franciscana nauplii and Penaeus vannamei postlarvae (PL2) after 48 and 38 h of challenge, respectively, with presumptive pathogenic bacterial strains.
| Bacterial strain | Mortality (%) | ||
|---|---|---|---|
| L15.12.2 | 74.2 ± 5.7 a | NI | |
| L15.13.2 | 77.5 ± 3.2 ab | NI | |
| L15.31.1 | 79.2 ± 3.2 ab | NI | |
| L15.29.2 | 80.8 ± 4.2 ab | NI | |
| L15.23.3 | 83.3 ± 5.4 ab | NI | |
| L15.26.1 | 83.3 ± 7.2 ab | NI | |
| L15.26.3 | 85.0 ± 5.8 abc | NI | |
| L15.5.2 | 87.5 ± 3.2 bd | NI | |
| L15.19.2 | 87.5 ± 6.9 bd | NI | |
| L15.25.3 | 95.0 ± 4.3 cde | 66.7 ± 13.0 a | |
| L15.29.1 | 95.8 ± 4.2 cde | 64.2 ± 12.6 a | |
| L15.23.1 | 96.7 ± 2.7 de | 61.7 ± 23.5 a | |
| L15.25.1 | 96.7 ± 2.7 de | 72.5 ± 17.9 a | |
| L15.21.1 | 97.5 ± 1.7 de | NI | |
| L15.21.2 | 97.5 ± 3.2 de | 70.9 ± 18.3 a | |
| L15.11.2 | 97.5 ± 3.2 de | 77.5 ± 3.2 a | |
| L15.10.3 | 98.3 ± 1.9 de | 86.6 ± 22.5 a | |
| L15.12.1 | 98.3 ± 3.3 de | 51.7 ± 10.4 a | |
| L15.10.4 | 99.2 ± 1.7 e | 83.4 ± 4.7 a | |
| L15.19.1 | 100.0 ± 0 | 71.7 ± 20.8 a | |
| Negative control | 0 ± 0 | 5.8 ± 9.6 | |
NI: strain not included in the challenge test. Means with different letters within a column indicate significant differences at P ≤ 0.05 by ANOVA and Tukey’s Honest Significant Difference tests.
Fig 1Phylogenetic tree of complete 16S rRNA sequences of the pathogenic circulating strains.
The analysis included 11 related Vibrio pathogen sequences reported in GenBank. Listonella anguillarum was used as outgroup (GenBank accession no. AM235737). The evolutionary history was inferred by using the Maximum Likelihood method based on the General Time Reversible model. A discrete Gamma distribution was used to model evolutionary rate differences among sites (5 categories, +G, parameter = 0.1000). The rate variation model allowed for some sites to be evolutionarily invariable ([+I], 9.76% sites). Bootstrap values (percentage of 1000 replicates) appear next to each corresponding branch. The tree was built with the Maximum Likelihood inference method, which was supported by the trees built with Maximum Parsimony, Neighbor Joining and Bayesian inference methods. * indicates luminescent strain.
Multiple antibiotic resistance (MAR) and susceptibility of pathogenic circulating strains to antibiotics and commercial probiotics, through the results of the antibiogram tests.
| Bacterial strain | Antibiotic susceptibility | Probiotic susceptibility | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P | T | TE | FF | FUR | CIP | NOR | NAL | E | C | F | MAR index | P1 | P2 | P3 | P4 | P5 | |
| L15.25.1 | R | R | R | S | S | S | S | S | S | S | S | 0.27 | R | R | S | R | I |
| L15.13.2 | R | I | R | S | S | S | S | S | S | S | S | 0.27 | I | S | S | S | S |
| L15.31.1 | R | R | S | S | S | S | S | S | S | S | S | 0.18 | R | R | S | S | S |
| L15.19.2 | R | R | S | S | S | S | S | S | S | S | S | 0.18 | R | R | R | R | S |
| L15.26.1 | R | R | S | S | S | S | S | S | S | S | S | 0.18 | S | S | R | R | S |
| L15.10.3 | R | R | R | S | S | S | S | S | S | S | S | 0.27 | R | R | R | R | I |
| L15.29.1 | R | R | R | R | S | S | S | S | S | S | S | 0.36 | R | R | R | R | S |
| L15.21.2 | R | I | S | S | S | S | S | S | S | S | S | 0.18 | R | R | R | R | S |
| L15.5.2 | R | R | R | S | S | S | S | S | S | S | S | 0.27 | S | R | R | R | S |
| L15.12.2 | R | R | S | S | S | S | S | S | S | S | S | 0.18 | R | R | R | R | S |
| L15.19.1 | R | R | I | S | S | S | S | S | S | S | S | 0.27 | R | R | R | R | S |
| L15.25.3 | R | R | S | S | S | S | S | S | S | S | S | 0.18 | R | S | S | I | S |
| L15.26.3 | R | R | R | S | S | S | S | S | S | S | S | 0.27 | I | R | R | R | S |
| L15.21.1 | R | R | S | S | S | S | S | S | S | S | S | 0.18 | S | R | R | R | S |
| L15.11.2 | R | R | S | S | S | S | S | S | I | S | S | 0.27 | R | R | I | I | S |
| L15.23.3 | R | R | S | S | S | S | S | S | I | S | S | 0.27 | S | I | S | S | S |
| L15.23.1 | R | R | S | S | S | S | S | S | S | S | S | 0.18 | R | R | R | R | S |
| L15.12.1 | R | R | S | S | S | S | S | S | S | S | S | 0.18 | S | R | R | R | S |
| L15.10.4 | R | R | I | S | S | S | S | S | S | S | S | 0.27 | R | R | R | R | I |
| L15.29.2 | R | I | S | S | S | S | S | S | S | S | S | 0.18 | R | R | S | R | S |
Antibiotics: penicillin (P), oxytetracycline (T), tetracycline (TE), fosfomycin (FF), furazolidone (FUR), ciprofloxacin (CIP), norfloxacin (NOR), nalidixic acid (NAL), enrofloxacin (E), chloramphenicol (C) and florfenicol (F). Probiotics: P1, P2, P3, P4 and P5. Susceptibility of the pathogenic circulating strains to antibiotics and probiotics are expressed as sensitive (S), intermediate (I) and resistant (R).
Patterns of multiple antibiotic resistance (MAR) and MAR index.
| Number of bacterial strains | MAR pattern | MAR index |
|---|---|---|
| 10 | P-T | 0.18 |
| 7 | P-T-TE | 0.27 |
| 2 | P-T-E | 0.27 |
| 1 | P-T-TE-FF | 0.36 |
Penicillin (P), oxytetracycline (T), tetracycline (TE), enrofloxacin (E) and fosfomycin (FF).
Results of minimal inhibitory concentration (MIC) tests for authorized antibiotics for use in aquaculture, organic acids and essential oils on the growth of pathogenic circulating strains.
| Bacterial strain | Minimal inhibitory concentration (μg mL-1) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antibiotic | Organic acid | Essential oil | |||||||||||
| T | F | OA1 | 0A2 | 0A3 | 0A4 | 0A5 | 0A6 | 0A7 | 0A8 | OA9 | EO1 | EO2 | |
| L15.12.1 | 500 | 5 | >3500 | >3500 | >3500 | 2500 | >3500 | 2500 | 2500 | >3500 | 100 | 1000 | 3000 |
| L15.12.2 | 500 | 8 | >3500 | >3500 | >3500 | 200 | >3500 | 2500 | 2500 | >3500 | 300 | 1000 | >3000 |
| L15.5.2 | >3500 | 2 | >3500 | >3500 | >3500 | 2500 | >3500 | 2500 | 2500 | >3500 | 400 | 2000 | >3000 |
| L15.21.1 | 100 | 4 | >3500 | >3500 | >3500 | 2500 | >3500 | 2500 | 2500 | >3500 | 400 | 2000 | 3000 |
| L15.21.2 | 5 | 8 | >3500 | >3500 | >3500 | 2500 | >3500 | 2500 | 2500 | >3500 | 400 | 900 | 3000 |
| L15.23.1 | 20 | 10 | >3500 | >3500 | >3500 | 2500 | >3500 | 2500 | 2500 | >3500 | 400 | 2000 | >3000 |
| L15.23.3 | 100 | 40 | >3500 | >3500 | >3500 | 2500 | >3500 | 2500 | 2500 | >3500 | 400 | 2000 | >3000 |
| L15.25.1 | >3500 | 4 | >3500 | >3500 | >3500 | 2500 | >3500 | 2500 | 2500 | >3500 | 500 | 200 | >3000 |
| L15.25.3 | 250 | 40 | >3500 | >3500 | >3500 | 2500 | >3500 | 2500 | 2500 | >3500 | 400 | 2000 | >3000 |
| L15.26.1 | 100 | 5 | >3500 | >3500 | >3500 | 2500 | >3500 | 2500 | 2500 | >3500 | 200 | 2000 | 3000 |
| L15.26.3 | 50 | 20 | >3500 | >3500 | >3500 | 2500 | >3500 | 2500 | 2500 | >3500 | 100 | 2000 | 3000 |
| L15.13.2 | 500 | 20 | >3500 | >3500 | >3500 | 2500 | >3500 | 1500 | 300 | >3500 | 500 | 2000 | >3000 |
| L15.11.2 | 10 | 8 | >3500 | >3500 | >3500 | 2500 | >3500 | 200 | 2500 | >3500 | 200 | 2000 | >3000 |
| L15.29.1 | 200 | 5 | >3500 | >3500 | >3500 | 2500 | >3500 | 500 | 2500 | >3500 | 200 | 1000 | >3000 |
| L15.29.2 | 200 | 8 | >3500 | >3500 | >3500 | 2500 | >3500 | 1000 | 2500 | >3500 | 2500 | 2000 | >3000 |
| L15.10.3 | 500 | 8 | >3500 | >3500 | >3500 | 600 | >3500 | 1000 | 300 | >3500 | 300 | 2000 | >3000 |
| L15.10.4 | 5 | 2 | >3500 | >3500 | >3500 | 1500 | >3500 | 2500 | 2500 | >3500 | 200 | 2000 | >3000 |
| L15.19.1 | 500 | 8 | >3500 | >3500 | >3500 | 2500 | >3500 | 2500 | 2500 | >3500 | 200 | 2000 | 3000 |
| L15.19.2 | 200 | 8 | >3500 | >3500 | >3500 | 2500 | >3500 | 2500 | 2500 | >3500 | 200 | 3000 | 3000 |
| L15.31.1 | 5 | 5 | >3500 | >3500 | >3500 | 2500 | >3500 | 2500 | 2500 | >3500 | 100 | 3000 | 3000 |
Antibiotics: oxytetracycline (T) and florfenicol (F); Organic acids: OA1, OA2, OA3, OA4, OA5, OA6, OA7, OA8 and OA9; Essential oils: EO1 and EO2. Maximum concentration analyzed: 3500 (oxytetracycline and organic acids) and 3000 (essential oils) μg mL-1.
Cell viability (%) of P. vannamei shrimp haemocytes after exposure at varied concentrations of authorized antibiotics for use in aquaculture and the two most effective natural products against pathogenic circulating bacterial strains.
| Concentration of products (μg mL-1) | Product | |||
|---|---|---|---|---|
| F | T | OA6 | OA9 | |
| 100 | 98.6 ± 4.7 d | 97.2 ± 2.7 b | 99.0 ± 1.5 c | 23.6 ± 2.4 a |
| 200 | 98.6 ± 5.0 d | 99.2 ± 0.9 b | 99.6 ± 0.6 c | 24.2 ± 3.4 a |
| 400 | 98.6 ± 3.4 d | 97.7 ± 2.7 b | 97.5 ± 2.5 c | 23.4 ± 3.1 a |
| 500 | 98.6 ± 5.3 d | 98.5 ± 2.4 b | 89.2 ± 2.6 b | 22.5 ± 1.5 a |
| 1000 | 96.1 ± 4.7 d | 98.7 ± 1.2 b | 26.4 ± 1.5 a | 21.9 ± 1.0 a |
| 2000 | 90.0 ± 3.1 d | 97.7 ± 4.3 b | 24.3 ± 2.0 a | - |
| 2500 | 72.0 ± 6.8 c | 97.7 ± 2.0 b | 22.1 ± 1.8 a | - |
| 3000 | 62.0 ± 3.7 bc | 92.7 ± 4.0 b | 22.7 ± 0.9 a | - |
| 4000 | 58.7 ± 4.7 b | 92.7 ± 3.1 b | - | - |
| 5000 | 44.3 ± 2.0 a | 84.3 ± 1.5 a | - | - |
| 6000 | 37.7 ± 1.5 a | 79.0 ± 1.0 a | - | - |
| 7000 | 37.3 ± 1.2 a | 76.3 ± 4.0 a | - | - |
Organic acids: OA6 and OA9; Antibiotics: florfenicol (F) and oxytetracycline (T). Means with different letters within a column indicate significant differences at P ≤ 0.05 by ANOVA and Tukey´s Honest Significant Difference tests.